Two Phase I/II , randomized , controlled studies were conducted to compare the immunogenicity and safety of investigational tetravalent HPV L1 virus-like particle ( VLP ) vaccines , containing VLPs from two additional oncogenic genotypes , with the licensed HPV-16 / 18 AS04-adjuvanted vaccine ( control ) in healthy 18-25 year-old women .